Significance of 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: it can be a specific marker for Lewy body disease
- PMID: 15515743
- DOI: 10.1007/BF02984560
Significance of 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: it can be a specific marker for Lewy body disease
Abstract
Recently, reliable and clear evidence for the usefulness of 123I-MIBG scintigraphy in the diagnosis of Parkinson's disease (PD) has been accumulated and it has become increasingly popular as one of the most accurate means of diagnosing the disease. PD, one of the most common neurodegenerative disorders, is characterized by resting tremor, rigidity, bradykinesia or akinesia, and postural instability. The disease is characterized pathologically by distinctive neuronal inclusions called Lewy bodies in many surviving cells of dopaminergic neurons of the substantia nigra pars compacta and other specific brain regions. Furthermore Lewy body type degeneration in the cardiac plexus has been observed in PD. In PD, cardiac MIBG uptake is reduced markedly even in the early disease stages; therefore, MIBG imaging can be used as an indicator of the presence of PD rather than disease severity. Other parkinsonian syndromes such as multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration demonstrate normal cardiac MIBG uptake or only mild reduction of MIBG uptake, indicating that MIBG imaging is a powerful method to differentiate PD from other parkinsonian syndromes. Dementia with Lewy bodies (DLB) also shows severe reduction of MIBG uptake, whereas Alzheimer's disease (AD) demonstrates normal MIBG uptake, permitting differentiation of DLB from AD using MIBG scintigraphy. In pure autonomic failure, which shares similar pathological findings with PD and is thought to be associated with diffuse loss of sympathetic terminal innervation, cardiac MIBG uptake also decreases markedly. Considering all the data together, marked reduction of cardiac MIBG uptake seems to be a specific marker of Lewy body disease and thus extremely useful in the differentiation from other diseases with similar symptoms without Lewy bodies.
Similar articles
-
[Clinical and pathological study on early diagnosis of Parkinson's disease and dementia with Lewy bodies].Rinsho Shinkeigaku. 2008 Jan;48(1):11-24. doi: 10.5692/clinicalneurol.48.11. Rinsho Shinkeigaku. 2008. PMID: 18386627 Review. Japanese.
-
123I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders.Mov Disord. 2009;24 Suppl 2:S732-41. doi: 10.1002/mds.22499. Mov Disord. 2009. PMID: 19877202 Review.
-
[The clinical significance of MIBG myocardial scintigraphy in Parkinson disease].Brain Nerve. 2012 Apr;64(4):403-12. Brain Nerve. 2012. PMID: 22481513 Review. Japanese.
-
(123)I-meta-iodobenzylguanidine (MIBG) cardiac scintigraphy in α-synucleinopathies.Ageing Res Rev. 2016 Sep;30:122-33. doi: 10.1016/j.arr.2016.01.001. Epub 2016 Feb 2. Ageing Res Rev. 2016. PMID: 26835846 Review.
-
Impaired myocardial 123I-metaiodobenzylguanidine uptake in Lewy body disease: comparison between dementia with Lewy bodies and Parkinson's disease.J Neurol Sci. 2006 Jan 15;240(1-2):15-9. doi: 10.1016/j.jns.2005.08.011. Epub 2005 Sep 29. J Neurol Sci. 2006. PMID: 16199056
Cited by
-
Plasma neurofilament light chain level and orthostatic hypotension in early Parkinson's disease.J Neural Transm (Vienna). 2021 Dec;128(12):1853-1861. doi: 10.1007/s00702-021-02423-y. Epub 2021 Sep 27. J Neural Transm (Vienna). 2021. PMID: 34568970
-
Ocular Vestibular-Evoked Myogenic Potential Assists in the Differentiation of Multiple System Atrophy From Parkinson's Disease.J Mov Disord. 2024 Oct;17(4):398-407. doi: 10.14802/jmd.24120. Epub 2024 Jul 9. J Mov Disord. 2024. PMID: 38977325 Free PMC article.
-
Comparative value of brain perfusion SPECT and [(123)I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease.Eur J Nucl Med Mol Imaging. 2006 Mar;33(3):248-53. doi: 10.1007/s00259-005-1921-x. Epub 2005 Nov 22. Eur J Nucl Med Mol Imaging. 2006. PMID: 16328506
-
Cerebrospinal fluid biomarkers for dementia with lewy bodies.Int J Alzheimers Dis. 2010 Oct 17;2010:536538. doi: 10.4061/2010/536538. Int J Alzheimers Dis. 2010. PMID: 21048932 Free PMC article.
-
Cardiac (123)I-metaiodobenzylguanidine imaging allows early identification of dementia with Lewy bodies during life.Eur J Nucl Med Mol Imaging. 2008 Sep;35(9):1636-41. doi: 10.1007/s00259-008-0828-8. Epub 2008 May 29. Eur J Nucl Med Mol Imaging. 2008. PMID: 18509631
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous